Yaxiong Zhang, Zihong Chen, Gang Chen, Yan Huang, Yunpeng Yang, W. Fang, Li Zhang
{"title":"对未经治疗的晚期表皮生长因子受体突变非小细胞肺癌患者进行ctDNA指导下的呋莫尼联合治疗或呋莫尼单药治疗的II期随机多中心研究设计:FOCUS-C 研究","authors":"Yaxiong Zhang, Zihong Chen, Gang Chen, Yan Huang, Yunpeng Yang, W. Fang, Li Zhang","doi":"10.1016/j.cllc.2024.06.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The design for a phase II, randomized, multicenter study of ctDNA-guided treatment with furmonertinib combined therapy or furmonertinib alone for untreated advanced EGFR mutant non-small cell lung cancer patients: The FOCUS-C study\",\"authors\":\"Yaxiong Zhang, Zihong Chen, Gang Chen, Yan Huang, Yunpeng Yang, W. Fang, Li Zhang\",\"doi\":\"10.1016/j.cllc.2024.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2024.06.002\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2024.06.002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
The design for a phase II, randomized, multicenter study of ctDNA-guided treatment with furmonertinib combined therapy or furmonertinib alone for untreated advanced EGFR mutant non-small cell lung cancer patients: The FOCUS-C study
期刊介绍:
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.